Home › Funds › Vivo Capital, LLC › LBRX
Vivo Capital, LLC position in LBRX
LB PHARMACEUTICALS INC · Health Care
Vivo Capital, LLC reported holding 800,000 shares of LBRX (LB PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$30.7M, representing 3.49% of its reported portfolio and ranking #11 among its reported holdings. Vivo Capital, LLC has disclosed LBRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's LBRX position evolved
Vivo Capital, LLC first disclosed a stake in LBRX in Q3 2025 at 800,000 shares (US$12.6M). The position peaked in Q3 2026 at 800,000 shares, worth US$30.7M. Across 5 filings, Vivo Capital, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 800,000 shares valued at US$30.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 800.00K | $12.63M | New |
| Q4 2025 | 800.00K | $17.81M | Hold |
| Q1 2026 | 800.00K | $19.73M | Hold |
| Q2 2026 | 800.00K | $25.96M | Hold |
| Q3 2026 | 800.00K | $30.70M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 106 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$108.8M), RA CAPITAL MANAGEMENT, L.P. (US$71.7M), Trails Edge Capital Partners, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $108.82M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $71.68M · Q2 2026
- Trails Edge Capital Partners, LP 1.52M sh · $49.43M · Q2 2026
- Commodore Capital LP 1.50M sh · $48.68M · Q2 2026
- TCG Crossover Management, LLC 1.45M sh · $46.97M · Q2 2026
- Caligan Partners LP 1.44M sh · $46.67M · Q2 2026
- Spruce Street Capital LP 1.38M sh · $44.66M · Q2 2026
- Nantahala Capital Management, LLC 1.05M sh · $34.17M · Q2 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $20.47M · Q2 2026
- Logos Global Management LP 585.00K sh · $18.99M · Q2 2026
- GREAT POINT PARTNERS LLC 317.22K sh · $10.30M · Q2 2026
- HighVista Strategies LLC 173.80K sh · $6.67M · Q3 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held LBRX?
Vivo Capital, LLC has disclosed LBRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Vivo Capital, LLC's current position in LBRX?
As of Q3 2026, Vivo Capital, LLC holds 800.00K shares of LBRX (LB PHARMACEUTICALS INC), valued at $30.70M, representing 3.49% of its reported portfolio and ranking #11.
Has Vivo Capital, LLC been buying or selling LBRX?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC held unchanged its position in LBRX. The position peaked in Q3 2026 at 800.00K shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Trails Edge Capital Partners, LP, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.